TACSTD2 and ovarian carcinoma: Our findings provide new insights and evidence for the platinum resistance mechanism of HGSOC, and offer new ideas and targets for the development of therapeutic strategies against TACSTD2+ epithelial cell subclusters, lay a profound foundation for the future use of TACSTD2 antibodies in the treatment of ovarian cancer.